In This Article:
March 5 - MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and BioNTech (BNTX, Financial). A Dusseldorf court ruled in favor of Moderna, according to a Wednesday court filing.
The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.
Pfizer and BioNTech exercised legal authorization to use their patent until May 2023. The court made a decision that Moderna legally withdrew their consent in March 2022 so their previous patent permission became void. Legal analysts view the court decision as a major advancement within pharmaceutical intellectual property rights that affects the industry.
Industry stakeholders and investors now watch closely for further updates in this high-stakes patent conflict.
This article first appeared on GuruFocus.